BackNeximmune Overview

Neximmune Current Cash

Neximmune's current cash is $2.4B.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$2.42B
↑ 14789.19% YoYΔ $2.41B vs prior year quarter

Peer trimmed avg / median

Loading

Neximmune Current Cash History

Loading

Neximmune vs. peers: Current Cash Comparison

Loading

Neximmune Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Neximmune (NEXI) FAQ

As of the most recent data (June 2024), NEXI shows a current cash of $2.4B. That compares with $16M in the prior-year period — up 14789.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NEXI's current cash is now $2.4B (was $16M) — a 14789.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Neximmune is outperforming or lagging.

Tracking NEXI's current cash over time shows whether Neximmune is scaling, shrinking, or reshaping that part of the business. The current reading is $2.4B That compares with $16M in the prior-year period — up 14789.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Neximmune's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $2.4B) with ownership activity and broader fundamentals.

Neximmune's current cash is $2.4B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.